Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2...

Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for...

Prof Nicolas Girard - Institut Curie, Paris, France

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Advance Prostate Cancer Consensus Conference 2021: Report

Prof Silke Gillessen and Prof Aurelius Omlin

Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )

Recent advances in the treatment of patients with exon 20 insertion-positive...

Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl

Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl )

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

ASCO GU 2022: Prostate roundup

Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore

ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )

METNET: A phase II trial of metformin in patients with well differentiated...

Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours ( Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari

EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE

Dr Neal Shore and Prof Kim Chi

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )

An AI-derived digital pathology-based biomarker to predict the benefit of ADT...

Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )

SG in combination with pembro in patients with mUC who progressed after...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

More from ecancer